Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. 1994

G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
Institute of 1st Obstetrics and Gynecological Clinic, University of Rome, La Sapienza, Italy.

OBJECTIVE To evaluate the effects on hormonal and metabolic variables and bone density of a transdermal system delivering estrogen and progestagen. METHODS Twenty-one patients were included in the study and randomly assigned to the following treatments: group A was treated with transdermal 17 beta-estradiol, 50 micrograms/day (Estraderm TTS 50), from the first to the fourteenth day of the cycle and with a transdermal combination of 17 beta-estradiol (50 micrograms/day) and norethisterone acetate (NETA) 250 micrograms/day during the following 14 days; group B was treated with Estraderm TTS 50 from the first to the twenty-eighth day, adding oral medroxyprogesterone acetate (MPA), 10 mg/day, during the final 14 days. DHEAS, testosterone, SHBG, prolactin, gonadotropins, and estrogens were measured in basal conditions and after 6 months' therapy. In the same schedule, lipid patterns (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), phosphocalcium variables (osteocalcin, calcitonin, parathormone), and bone mineral density were also studied. RESULTS Both treatments were efficient in reducing menopausal symptoms. An increase of DHEAS (P < .05) and a decrease of FSH and LH (P < .02, < .01, respectively) were observed in group B. No significant modifications in lipid and lipoprotein metabolism were shown in either group after 6 months. The calcium-regulating hormone osteocalcin (BCG) decreased significantly (P < .05) only in group A; calcitonin, parathormone, and bone density were unchanged after treatment. CONCLUSIONS Transdermal administration of estrogen plus progestagen reduces menopausal symptoms, but does not induce changes in metabolic variables and hormonal levels (androgens and prolactin).

UI MeSH Term Description Entries
D008525 Medroxyprogesterone A synthetic progestational hormone used in veterinary practice as an estrus regulator. (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione,Methylhydroxyprogesterone,Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-,17 alpha-Hydroxy-6 alpha-Methylprogesterone,Adgyn Medro,17 alpha Hydroxy 6 alpha Methylprogesterone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009640 Norethindrone A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION. 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)-,Ethinylnortestosterone,Norethisterone,Norpregneninolone,Conceplan,Micronor,Monogest,Nor-QD,Norcolut,Norcolute,Norethindrone, (1 beta)-Isomer,Norlutin,Nor QD,NorQD
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
August 1985, American journal of obstetrics and gynecology,
G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
October 1988, Steroids,
G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
January 1997, Fertility and sterility,
G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
February 1991, Gastroenterology,
G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
April 1991, Fertility and sterility,
G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
January 1998, Fertility and sterility,
G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
October 1991, Maturitas,
G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
August 1985, American journal of obstetrics and gynecology,
G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
September 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
G Perrone, and P Falaschi, and O Capri, and R Pastore, and P Galoppi, and R D'Urso, and A Martocchia, and G Anelli, and L Zichella
May 1989, Obstetrics and gynecology,
Copied contents to your clipboard!